The EAHP Board, elected for three-year terms, oversees the association’s activities. Comprising directors responsible for core functions, it meets regularly to implement strategic goals. Supported by EAHP staff, the Board controls finances, coordinates congress organization, and ensures compliance with statutes and codes of conduct.
CPS1 – Precision in practice: advancing patient care with model-informed precision dosing
Date:
12/03/2025 - 2:30 pm to 3:30 pm
13/03/2025 - 9:00 am to 10:30 am
Room:
Room 18+19
Facilitator:
Adrin Dadkhah
Speakers:
Abstract:
Link to EAHP Statements
Section 4 – Clinical Pharmacy: Statements – 4.1, 4.6, 4.8
Section 5 – Patient Safety and Quality Assurance: Statements – 5.1, 5.5
Abstract
Model-informed precision dosing (MIPD) is a promising tool in personalized medicine, offering a novel approach to drug therapy that exceeds traditional dosing guidelines.
The foundation of MIPD lies in the integration of pharmacokinetic (PK) and pharmacodynamic (PD) models with patient-specific data. By incorporating individual patient characteristics such as organ function, genetic makeup and concurrent medications, MIPD facilitates the shift from one-size-fits-all to a more individualized approach.
Therefore, the clinical application of MIPD offers the opportunity to increase drug efficacy and reduce adverse drug reactions, which is particularly crucial in therapeutic areas where the therapeutic window is narrow, such as oncology and critical care.
Advancements in computational tools have accelerated the development of pharmacometric models that enable clinicians to simulate various dosing scenarios and thereby offer guidance in dose selection and adjustment. However, the implementation of MIPD in clinical practice still faces challenges, including the need for interdisciplinary collaboration, education, and the integration of complex models into user-friendly decision support systems. Addressing these challenges is essential to implement MIPD into clinical routine and make use of its potential of tailoring treatments to meet the unique needs of each patient.
This seminar offers an overview of clinical applications for MIPD and discusses requirements and challenges regarding its implementation into clinical practice.
Learning objectives
After the session the participants should be able to:
- Define the advantages of MIPD in comparison to conventional Therapeutic Drug Monitoring (TDM).
- List the potential barriers and limitations for implementation
Educational need addressed
Hospital pharmacists take a key part in interpreting TDM. Learning new approaches in TDM is essential for an improvement of a pharmaceutical care.
Keywords
Pharmacokinetics, precision medicine approach, drug dosing.